Crescent Biopharma, Inc. - Common Stock (CBIO)

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the merger of Catalyst Biosciences, Inc. (NasdaqCM: CBIO) and GNI Group Ltd. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company’s shareholders.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating Catalyst Biosciences, Inc. (NasdaqCM: CBIO) in connection with its acquisition of the F351 program, a next-generation fibrosis drug, from GNI Group Ltd. and, in a separate transaction, its acquisition of a controlling interest in Beijing Continent for 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock (Series X) with economic rights equivalent to Catalyst’s common stock. Each share of Series X preferred stock is convertible into 10,000 shares of common stock, subject to stockholder approval under Nasdaq rules and subject to a beneficial ownership conversion blocker. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company’s shareholders.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Catalyst Biosciences, Inc. (NASDAQ: CBIO) and GNI Group Ltd. is fair to Catalyst shareholders.

JDS1, LLC (“JDS1”), which collectively with the other reporting persons in its Section 13(d) group, beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst” or the “Company”), commented today on its previously announced withdrawal of the director nominations and other proposed business that it had intended to bring before the upcoming 2022 Annual Meeting of Stockholders of Catalyst Biosciences, Inc.

JDS1, LLC, which collectively with the other participants in its solicitation beneficially owns approximately 8.4% of the outstanding common stock of Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst” or the “Company”), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission and sent a letter to its fellow stockholders. JDS1 is urging shareholders to vote on the GOLD proxy card to elect its slate of three highly-qualified nominees – Shelly Lombard, Matthew Stecker, and Igor Volshteyn – to Catalyst’s eight-member Board of Directors at Catalyst’s 2022 Annual Meeting of Stockholders to be held in person on August 15, 2022. In its letter to stockholders, included below, JDS1 again calls for Catalyst to firmly, and unequivocally, commit to a distribution to stockholders of most of its available cash at the earliest possible time.